With its versatile and powerful TEMPO epigenomic control platform, Tune Therapeutics is pioneering a new therapeutic modality that can fine-tune any gene network and unlock the full power and potential of regenerative medicine.

With deep experience and a passionate commitment to exploration and innovation, Tune is driving through an inflection point in the history of genetic medicine: from targeting a limited range of rare conditions, to addressing thousands of common and complex diseases for which no curative treatment is available.

Biotechnology

Education

Tune Therapeutics

Charles A. Gersbach

Jason Dean

Kendra Congdon

Tyler Goodwin

Zachary Hale

Georgeta Puscalau

Katherine H.

Michael P. Hefferan

Derek Jantz

Christina Jordan

Glenn Murphy

Luis Sanchez-Perez

Shannon Grace

Ryan Tam

The Research and Development team at Tune Therapeutics focuses on advancing the TEMPO epigenomic control platform to explore innovative therapeutic strategies for regenerative medicine. Comprising experts from various scientific backgrounds, the team conducts rigorous research, develops novel products, and translates epigenomic insights into effective treatments for complex diseases. Their collaborative efforts aim to unlock new pathways in genetic medicine, addressing a wide range of conditions previously deemed untreatable.

Research and Development

Technical Operations and Engineering

Leadership Team

Research and Development

About

Team members

Other teams at Tune Therapeutics

Technical Operations and Engineering

Leadership Team